To the full analysis
PharmaEssentia stock: growth
6446.TWPharmaEssentia reported $475.94M in revenue for fiscal 2025, up 60.6% on the prior year, up 94.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
46.1%
per year from 2010 to 2025, per share 36.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2010 | |
|---|---|---|---|
| Revenue | 94.8% | 105.6% | 46.1% |
| Revenue per share | 83.2% | 94.9% | 36.8% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2010 | $1.62M | −$5.09M | −$2.77M |
| 2011 | $479.7K | −$6.2M | −$5.88M |
| 2012 | $866.79K | −$7.79M | −$11.03M |
| 2013 | $2.2M | −$18.06M | −$10.76M |
| 2014 | $406.58K | −$25.97M | −$23.57M |
| 2015 | $352.79K | −$25.97M | −$17.02M |
| 2016 | $166.61K | −$25.72M | −$20.79M |
| 2017 | $122.83K | −$26.55M | −$24.92M |
| 2018 | $798.66K | −$31.65M | −$29.76M |
| 2019 | $9.31M | −$25.66M | −$32.44M |
| 2020 | $16.96M | −$59.3M | −$50.62M |
| 2021 | $19.98M | −$85.57M | −$77.93M |
| 2022 | $87.73M | −$41.85M | −$55.59M |
| 2023 | $155.42M | −$18.99M | −$61.9M |
| 2024 | $296.34M | $90.27M | $50.03M |
| 2025 | $475.94M | $153.58M | $102.68M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = NT$32.8500)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 22 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.